Sign In
Buy PFS
$21.54
-0.710 (-3.19%)
At Close: Jun 03, 2026
Further positive results from the Phase III SERENA-6 trial showed AstraZeneca's camizestrant plus a cyclin-dependent kinase (CDK) 4/6 inhibitor â palbociclib
IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Li
Hengrui Pharma Presents More Than 90 Oncology Studies at ASCO 2026, Highlighting Progress Across Multiple Tumor Types
02:00am, Monday, 01'st Jun 2026
Hengrui Pharma Presents More Than 90 Oncology Studies at ASCO 2026, Highlighting Progress Across Multiple Tumor Types PR Newswi
Summit Therapeutics Inc. (NASDAQ: SMMT) today announced positive overall survival (OS) results from the Phase III HARMONi-6 trial, conducted in China and spons
Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer
09:00am, Sunday, 31'st May 2026
[url="]Pfizer Inc. [/url](NYSE: PFE) today announced detailed progression-free and overall survival results from Cohort 3, a randomized cohort of the Phase 3 B
Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026
09:00pm, Saturday, 30'th May 2026
Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026
[url="]Exelixis, Inc.[/url] (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal trial, which showed that CABOMETYXÂ
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (MonjuviÂ/Min
Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026
09:00am, Saturday, 30'th May 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) today presented new results from the AK112-206 trial (NCT05382442), a global, open-label, multicenter Phase II study in
[url="]Immunome, Inc.[/url] (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today a
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the latest results from its missi
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026
07:00am, Friday, 29'th May 2026
[url="]BeOne Medicines Ltd.[/url] (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocyti
Dudick Promoted to SVP, Team Leader at Provident Bank
08:00am, Wednesday, 27'th May 2026
ISELIN, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- Provident Bank , a leading New Jersey-based financial institution has announced that Jessica Dudick has been promoted to Senior Vice President, Team Lead
WuXi Biologics Achieves GMP Release of 18th Drug Product Facility, Advancing Integrated Drug Substance to Drug Product Capabilities
06:00am, Wednesday, 27'th May 2026
WuXi Biologics Achieves GMP Release of 18th Drug Product Facility, Advancing Integrated Drug Substance to Drug Product Capabilities
Black Diamond Therapeutics Lung Cancer Drug Shows 15.2-Month PFS in Phase 2 Study
07:09pm, Thursday, 21'st May 2026
Black Diamond Therapeutics NASDAQ: BDTX reported updated Phase 2 data for silevertinib in treatment-naive non-small cell lung cancer patients with EGFR Non-Classical Mutations, saying the investigatio
